Skip to main
AVTX
AVTX logo

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics (AVTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avalo Therapeutics has demonstrated significant upward momentum, evidenced by a pre-market increase of approximately 22%, which reflects growing market confidence in AVTX-009's potential to address hidradenitis suppurativa (HS). The upcoming LOTUS data readout is anticipated to further enhance investor sentiment as the therapeutic capabilities of AVTX-009 become increasingly recognized. Additionally, the overall market for HS therapies is expected to expand, driven by a trend towards more effective and sustained treatment options, positioning Avalo favorably within this evolving landscape.

Bears say

Avalo Therapeutics exhibits a negative outlook primarily due to observed adverse events, specifically two cases of neutropenia, including one graded as Grade 3, which may raise concerns over the safety profile of its leading asset, AVTX-009. Furthermore, potential efficacy issues are highlighted by the capability of competing therapies, such as lutikizumab, to suffer from target distraction due to their dual binding properties, which could limit their effectiveness in treating inflammatory diseases. Additionally, the historically low rates of diagnosis and treatment in the relevant market, previously ascribed to a lack of effective therapies, may continue to hinder demand for Avalo's products.

Avalo Therapeutics (AVTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avalo Therapeutics (AVTX) Forecast

Analysts have given Avalo Therapeutics (AVTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Avalo Therapeutics (AVTX) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avalo Therapeutics (AVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.